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Ischemia-reperfusion injury (IRI) is a major cause of cardiac damage following various 
pathological processes. Gaseous hydrogen sulfide (H2S) is protective during IRI by inducing 
a hypometabolic state in mice that is associated with anti-apoptotic, anti-inflammatory 
and antioxidant properties. We investigated whether gaseous H2S administration is 
protective in cardiac IRI and whether non-hypometabolic concentrations of H2S have 
similar protective properties.
Male C57BL/6 mice received a 0, 10, or 100 ppm H2S-N2 mixture starting 30 minutes 
prior to ischemia until 5 min pre-reperfusion. IRI was inflicted by temporary ligation of 
the left coronary artery for 30 min. High-resolution respirometry equipment was used to 
assess CO2-production and blood pressure was measured using internal transmitters. The 
effects of H2S were assessed by histological and molecular analysis.
Treatment with 100 ppm H2S decreased CO2-production by 72%, blood pressure 
by 14% and heart rate by 25%, while treatment with 10 ppm had no effects. At day 
1 of reperfusion 10 ppm H2S showed no effect on necrosis, while treatment with 100 
ppm H2S reduced necrosis by 62% (P<0.05). Seven days post-reperfusion, both 10 ppm 
(P<0.01) and 100 ppm (P<0.05) H2S showed a reduction in fibrosis compared to IRI 
animals. Both 10 ppm and 100 ppm H2S reduced granulocyte-influx by 43% (P<0.05) 
and 60% (P<0.001), respectively. At 7 days post-reperfusion both 10 and 100 ppm H2S 
reduced expression of fibronectin by 63% (P<0.05) and 67% (P<0.01) and ANP by 84% 
and 63% (P<0.05), respectively.
Gaseous administration of H2S is protective when administered during an cardiac 
ischemic insult. Although hypometabolism is restricted to small animals, we now showed 
that low non-hypometabolic concentrations of H2S also have protective properties in 
IRI. Since IRI is a frequent cause of myocardial damage during percutaneous coronary 
intervention and cardiac transplantation, H2S treatment might lead to novel therapeutic 
modalities.




Ischemia-reperfusion injury (IRI) is the most important cause of myocardial damage and 
subsequent heart failure. Although IRI is most frequently caused by acute myocardial 
infarction (MI) with (early or late) reperfusion, it can also be observed following surgical 
procedures such as cardiopulmonary bypass or cardiac transplantation.1,2 Myocardial 
IRI causes acute tissue responses characterized by inflammation and upregulation of 
inflammatory mediators. This process ultimately leads to irreversible fibrotic damage.3,4 
Despite major therapeutic developments, cardiovascular disease remains the leading cause 
of death in the western world.5
Hydrogen sulfide (H2S) has drawn considerable attention for its role in various 
(patho)physiological processes. It is, in addition to nitric oxide and carbon monoxide, 
acknowledged as the third gasotransmitter, sharing many functions with these gases.6 H2S 
is endogenously produced and exerts fine, modulatory control over cellular functions by 
influencing an array of intracellular signaling processes. H2S-producing enzymes and H2S-
plasma levels are reduced in various diseases.7-9 Exogenously administered H2S can reversibly 
induce a hypometabolic state in mice, during which it rapidly reduces O2-consumption, 
CO2-production, core body temperature, heart rate and breathing frequency.
10,11
The most probable mechanism for these properties is the reversible inhibition of 
mitochondrial O2-consumption and ATP-production through non-permanent binding 
of sulfide to the terminal enzyme in the electron transport chain, cytochrome c oxidase 
(complex IV).12It was thought that the reduced demand for oxygen during hypometabolism 
might be one of the protective mechanisms during ischemia. However, H2S is also 
considered protective during other processes critically involved in myocardial IRI such as 
oxidation, inflammation and apoptosis. These cytoprotective features of H2S make it an 
attractive candidate for therapeutic reduction of the damaging effects of hypoxia.13,14
The influence of gaseous administration of H2S and the effects of hypometabolic 
and non-hypometabolic concentrations on the outcome of myocardial IRI remains to 
be elucidated. Some studies have explored the beneficial effects of soluble H2S donors 
such as NaHS and Na2S in myocardial IRI and other models of cardiac damage.
15-18 
The preference for gaseous administration above injection with H2S donors lies within 
accurate management of the concentration. As opposed to injection with soluble H2S 
donors, gaseous H2S is less difficult to dose and has a short wash-out period, leaving 
its positive effects behind.11 Moreover, gaseous administration has proven to induce a 
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hypometabolic state, while this has not been shown for intra-peritoneal or intra-venous 
administration of soluble H2S.
10,11 Although H2S does not appear to have hypometabolic 
effects in ambiently cooled large mammals, thereby questioning its therapeutic appli-
cations in humans, the beneficial effects of non-hypometabolic concentrations of H2S 
have not been studied.19,20 Since minimizing myocardial IRI has broad clinical implications 
and may have beneficial effects on cardiac surgical outcomes,1 we therefore investigated 
whether gaseous H2S-treatment attenuates myocardial IRI in mice and whether non-
hypometabolic concentrations exhibit similar protective properties.
Materials and Methods
Ethics Statement
Procedures were in agreement with institutional and legislator regulations and approved 
by the Committee on the Ethics of Animal Experiments of the University Medical Center 
Groningen. Utmost effort was utilized to prevent suffering and minimize the numbers of 
mice required for each experiment.
Animals
Male C57BL/6 mice (6-8 weeks, Harlan, Zeist, the Netherlands) were housed at our animal 
research facility under standard conditions with a 12h light:dark cycle with free access to 
water and chow.
Telemetry
Blood pressure was measured telemetrically (n=4) using transmitters (TA11PA-C10; 
Data Sciences International, St Paul, MN, USA). Devices were placed through a midline 
abdominal incision under anesthesia (2% Isoflurane) and mice were placed on a heating 
pad to maintain body temperature at 37°C. The catheter was placed in the aorta and the 
transmitter body in the abdominal cavity. Animals recovered 7 days before commencing 
measurements. Data were recorded as 10-second averages every minute using Dataquest 
ART data acquisition system (Data Sciences International). Animals were treated with room 
air or a H2S / air mixture in our respirometry system during measurements. For comparison 
of blood pressure and heart rate, the average of 20 minutes baseline measurement and 20 
minutes of 10 ppm and 100 ppm H2S treatment was determined. A crossover design was 
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used in which all animals received all treatments in randomized order.
Respirometry
Measurement of CO2-production was performed as described.
21 Compressed air and 
500 ppm H2S / N2 (Air Products, Amsterdam, the Netherlands) were mixed in a 4:1 ratio 
and in a 49:1 ratio resulting in a 100 ppm H2S / 17% O2 mixture and a 10 ppm H2S / 17% 
O2 mixture, respectively. CO2-production was corrected for body weight and normalized 
to mean control values. Animals (n=11) were treated in a crossover model in randomized 
order and all received room air, 10 ppm H2S and 100 ppm H2S on different days. Baseline 
CO2 measurements with room air were performed for 30 minutes followed by treatment 
with either a 10 or 100 ppm H2S / 17% O2 mixture for 30 minutes. Recovery with room 
air was measured for 30 minutes.
Myocardial ischemia/reperfusion and H2S treatment
Mice were intubated and mechanically ventilated (n=77) with an O2 / N2 mixture in a 4:1 
ratio, an O2 / 100 ppm H2S / N2 mixture in a 4:1 ratio or a O2 / 10 ppm H2S / N2 mixture 
in a 49:1 ratio at a frequency of 180/min with a tidal volume of 250 μl using a rodent 
ventilator (Harvard Midivent model 849). Treatment regimens (Sham n=15; IRI n=20; 10 
ppm n=21; 100 ppm n=21) were randomly assigned and started 30 minutes prior to 
ischemia until 5 minutes pre-reperfusion. Myocardial IRI was inflicted by temporary ligation 
of the left anterior descending coronary artery (6-0 prolene suture) for 30 min through 
an incision in the fourth intercostal space under anesthesia (75 mg/kg ketamine, 1 mg/
kg medetomidine). After removing the ligature the heart was inspected for restoration of 
blood flow and muscle and skin layers were sutured with 5.0 vicryl. Body temperature was 
monitored with a rectal probe and maintained at 37°C using heat pads. Sham operated 
animals underwent the same procedure, except the placement of the ligature. Post-
operatively, all mice received a subcutaneous injection of 50 µg/kg buprenorphin (Schering-
Plough) for analgesic purposes and were allowed to recover from surgery at 37°C in a 
ventilated incubator. After 1 and 7 days mice were anaesthetized with 2% isoflurane in 
O2 for collection of blood and organs. Blood was collected in heparin containing tubes, 
centrifuged for 10 minutes at 1000 rcf and plasma was collected and stored at -80°C. The 
hearts were rapidly excised and mid-papillary slices were fixed in 4% paraformaldehyde, 
paraffin-embedded and sections were cut for immunohistochemical analysis. Apical parts 




Cardiac damage was assessed by measuring high sensitive (hs) Troponin-T in plasma 
samples using a standard electrochemiluminescence immunoassay (Roche) in the clinical 
chemical laboratory.
Histopathological scoring
At 1 day of reperfusion the extent of necrosis was determined in haematoxylin-eosin 
stained sections. At 7 days of reperfusion the extent of fibrosis was determined in Masson 
stained sections. Both were examined in a blinded fashion. Sections were scanned using 
an Aperio ScanScope GS (Aperio Technologies, Vista, CA, USA). Total cardiac area, 
necrotic cardiac area and fibrotic cardiac area were determined using Aperio Imagescope 
software, and the ratio of necrotic cardiac surface area and fibrotic surface area to total 
cardiac surface area were determined. Representative photomicrographs were artificially 
colored indicating the extent of damage.11,21
Immunohistochemistry for Ly-6G
For granulocytes, paraffin-embedded sections were stained for Ly-6G using rat-anti-
mouse Ly6G/C-FITC IgG2b antibody (AbCam, Cambridge, MA, USA), followed by rabbit-
anti-FITC and HRP-conjugated goat-anti-rabbit antibodies. Slides were scanned using an 
Aperio ScanScope GL (Aperio Technologies, Vista, CA, USA) and analyzed for positive 
pixel area (Ly-6G) using the Aperio Positive Pixel Analysis v9.1 algorithm.
Qualitative Real-Time Polymerase Chain Reaction
RNA extraction, DNAase treatment21 and cDNA synthesis22 were performed as described. 
A relative quantification PCR was performed to determine gene expression (Applied 
Biosystems, Foster City, CA). b-actin and GAPDH were used as housekeeping genes.
















PCR was performed in a volume of 20 µl containing 10 ng cDNA and 15 µl PCR 
mastermix (SYBR GREEN Applied Biosystems; 5 ml P/N 4309155). The Thermal Profile 
was performed as described.22 The average Ct-values for fibronectin, ANP, NOX2 and 
NOX4 were subtracted from the average β-actin Ct-values and the average of β-actin 
and GAPDH Ct-values to yield the delta Ct. Results were expressed as 2-ΔCt.
Cell culture
The H9c2 cell line (ATCC) is an immortalized line with characteristics of rat heart 
myoblasts. Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM; Lonza, 
Germany) containing 4.5 g/l glucose, 10% fetal calf serum (FCS; Bodinco, Alkmaar, the 
Netherlands), L-glutamine and penicillin (100 U/ml) streptomycin (100 µg/ml) (Lonza, 
Germany). Cells were cultured using 75 cm2 collagen coated flasks (Corning, Schiphol-
Rijk, Netherlands) in a humidified atmosphere of 5% CO2 and 95% O2 at 37 ºC.
In vitro model of oxidative stress
H9c2 cells grown to 80-90% confluency were harvested using 3 ml trypsin EDTA (200 
mg/l) after washing twice with Hank’s Buffered Salt Solution (HBSS) (Lonza; Germany). 
Cells were cultured in a 24-well plate at a density of ~10.000 cells/well in 0.5 ml medium. 
After 24 hours cells were loaded with 15 μM Dihydroethidine (DHE). Culture plates were 
placed in a humidified chamber with 5% CO2 on an automated inverted fluorescent 
microscope system (TissueFAXS system, TissueGnostics GMBH, Vienna, Austria) which 
makes sequential photomicrographs of 9 area’s in each well every 5 minutes. After 
baseline measurements, cells were exposed to Antimycin (50 μg/mL) and NaHS (donor 
of H2S in solution) in a concentration of 1 mM. Fluorescence intensity of every cell was 




Data were analyzed using GraphPad PRISM 5.0 (GraphPad, San Diego, CA, USA) using 
two-way ANOVA, Mann-Whitney U, Friedman or Kruskall Wallis tests where appropriate. 
Bonferroni or Dunns post-hoc analysis was applied where multiple comparisons were 
made. Normality was tested using the Kolmogorov–Smirnov test. P<0.05 was considered 
statistically significant. All data are expressed as mean ± SEM (Standard Error of the Mean) 
unless otherwise indicated.
Results
Effect of H2S on CO2 production, blood pressure and heart rate
Within 15 minutes of treatment with 100 ppm H2S induced a state of hypometabolism, 
concomitant with a reduction in CO2-production by an average of 72% compared to 
basal levels (P<0.001). Cessation of H2S resulted in a rapid recovery of CO2-production, 
where CO2 concentrations raised to basal levels within 30 minutes (P<0.001). 100 ppm 
H2S lowered blood pressure with 14% (103 vs. 120 mmHg, P<0.05) and heart rate with 
25% compared to baseline (502 vs. 670 beats per minute, P<0.05) 10 ppm H2S had no 
effect on CO2 production, blood pressure and heart rate (Figure 1).
H2S reduces myocardial damage
At 1 day of reperfusion cardiac IRI induced significant necrosis (Figure 2A) in animals 
exposed to 0 ppm H2S when compared to sham animals (P<0.001) as indicated by infarct 
size. 10 ppm H2S did not reduce the size of the necrotic area, while 100 ppm H2S reduced 
infarct size by 62% (P<0.05) (Figure 2B). In mice treated with 10 ppm H2S hs Troponin-T 
levels were not reduced 1 day post-reperfusion, while 100 ppm H2S reduced hs Troponin-T 
levels by 47% (P<0.05) compared to IRI animals (Figure 2C). Fibrosis, as measured by 
collagen deposition in Masson stained sections (Figure 3A) at 7 days of reperfusion, was 
markedly increased in animals treated with 0 ppm H2S when compared to sham-operated 
animals (P<0.001). Treatment with either 10 or 100 ppm of H2S reduced collagen 
deposition to comparable levels (10 ppm: 59%, P<0.01; 100 ppm: 57%, P<0.05) (Figure 
3B). Cardiac mRNA levels of fibronectin, a marker of myocardial fibrosis, were massively 
increased in 0 ppm H2S treated animals (P<0.01), while no increase was detected in animals 
of both H2S treated groups (10 ppm H2S P<0.05; 100 ppm H2S P<0.01) (Figure 3C). 
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Seven days post-reperfusion hs Troponin-T levels were reduced by 59% (P<0.05) and 
75% (P<0.01) in 10 ppm and 100 ppm H2S treated mice, respectively (Figure 3D).
Figure 1 - High concentrations of H2S induce a state of hypometabolism. Within 15 minutes 
(A) CO2-production decreased by 72% (***P<0.001) in mice (n=11) subjected to 100 ppm H2S. 
Exposure to 10 ppm H2S (n=11) did not induce a reduction in CO2 production in these animals. 
Cessation of gaseous H2S resulted in rapid recovery, within 30 minutes CO2 levels returned back 
to baseline concentrations (***P<0.001). Administration of 100 ppm H2S (n=4) resulted in a 14% 
decrease in (B) mean arterial pressure and a 25% decrease in (C) heart rate (*P<0.05). However 
exposure to 10 ppm H2S (n=4) had no effect on mean arterial pressure or heart rate.
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Figure 2 - Cardiac damage is reduced by 100 ppm H2S at 1 day of reperfusion. (A) Representative 
photomicrographs of haematoxylin-eosin stained cardiac sections with necrotic area artificially 
colored red, indicating the extent of necrotic damage found in each group at 1 day of reperfusion. 
(B) Cardiac IR induced a significant amount of necrosis in IRI animals exposed to 0 ppm H2S (### 
P<0.001 vs. sham). In animals treated with 100 ppm H2S necrosis was reduced by 62% (* P<0.05 
vs. IRI) where as 10 ppm H2S had no effect on necrosis. (C) At 1 day of reperfusion hs Troponin-T 
levels were elevated in IRI animals exposed to 0 ppm H2S (## P<0.01 vs. sham). In the 100 ppm H2S 
treated group hs Troponin-T levels were reduced compared to 0 ppm treated animals (* P<0.05), 
10 ppm H2S had no effect.
 
ANP-gene expression
mRNA expression of atrial natriuretic peptide (ANP), a marker for induction of the fetal 
gene program, was significantly increased in hearts of mice treated with 0 ppm H2S 
compared to sham-operated animals at 7 days of reperfusion. In hearts of 10 and 100 
ppm H2S treated mice the relative ANP expression was significantly reduced compared to 
mice treated with 0 ppm H2S (P<0.05) (Figure 3E).
Inflammation
One day post-reperfusion, Ly-6G-positive granulocytes were increased 12-fold in animals 
treated with 0 ppm H2S compared to sham-operated animals (P<0.001). Exposure to 
10 ppm and 100 ppm H2S reduced granulocytes by 43% (P<0.05) and 60% (P<0.001), 
respectively (Figure 4).
A Sham 0 ppm 10 ppm 100 ppm
B
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Figure 3 - Cardiac damage is reduced by 10 and 100 ppm H2S at 7 days of reperfusion. (A) 
Representative photomicrographs of Masson stained cardiac sections with fibrotic area artificially 
colored red, indicating the extent of fibrotic damage found in each group at 7 days of reperfusion. (B) 
Cardiac IR induced a significant amount of fibrosis in IRI animals exposed to 0 ppm H2S (### P<0.001 
vs. Sham). In animals treated with 10 ppm and 100 ppm H2S fibrosis was significantly reduced 
(**P<0.01, * P<0.05 vs. IRI). (C) Expression of fibronectin at 7 days of reperfusion was increased 
in IRI animals (## p<0.01 vs. sham). Treatment with 10 and 100 ppm H2S reduced the expression 
of fibronectin (*P<0.05, ** P<0.01 vs. IRI). (D) Seven days post-reperfusion hs Troponin-T levels 
were elevated in IRI animals exposed to 0 ppm H2S (# P<0.01 vs. sham). Both 10 and 100 ppm 
H2S reduced hs Troponin-T levels by 59% and 75%, respectively, as compared to animals treated 
with 0 ppm (*P<0.05, ** P<0.01 vs. IRI). (E) Expression of ANP mRNA at 7 days of reperfusion was 
increased in IRI animals (## p<0.01 vs. Sham). Treatment with 10 and 100 ppm H2S reduced the 
expression of ANP (*P<0.05 vs. IRI).
A Sham 0 ppm 10 ppm 100 ppm
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Figure 4 - H2S reduces cardiac IRI induced inflammation. There was a marked increase in granulocyte 
influx after cardiac ischemia (P<0.001) compared to sham animals. Exposure to 10 ppm and 100 ppm 
H2S significantly reduced the influx of granulocytes in the infarct area (10 ppm P<0.05; 100 pm 
P<0.001). Below are representative images from these stainings: (A) Sham (B) IRI, 0 ppm H2S (C) IRI, 
10 ppm H2S (D) IRI, 100 ppm H2S.
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NOX2 and NOX4 gene expression
To investigate ROS-related genes in vivo, we measured mRNA expression of nicotinamide 
adenine dinucleotide phosphate oxidase 2 and 4 (NOX2 and NOX4). At 1 day of 
reperfusion no significant differences were found in NOX2 and NOX4 mRNA expression. 
Seven days post-reperfusion, NOX2 and NOX4 expression were significantly increased 
in hearts of mice treated with 0 ppm H2S compared to sham operated animals (NOX2: 
p<0.05, NOX4: P<0.01). NOX2 and NOX4 expression were not amplified in hearts of 
mice treated with 10 and 100 ppm H2S compared to mice treated with 0 ppm H2S 
(P<0.05) (Figure 5A and B).
Effect of H2S on ROS production in vitro
Antimycin A induced ROS production in cultured H9c2 rat cardiomyoblasts was 
significantly reduced by treatment with NaHS. Live cell imaging of DHE fluorescence 
showed a massive increase in cytoplasmatic ROS production during treatment with 
Antimycin, whereas addition of NaHS to the medium markedly reduced this fluorescence 
signal (P<0.001) (Figure 6).
Figure 5 - H2S attenuates NOX2 and NOX4 upregulation. Expression of (A) NOX2 and (B) NOX4 
mRNA was increased in IRI animals at 7 days post-reperfusion (NOX2: # P<0.05, NOX4: ## P<0.01 vs. 
Sham). Treatment with 10 and 100 ppm H2S reduced the expression of both genes (*P<0.05 vs. IRI). 






Figure 6 - H2S reduces ROS production in cultured cardiomyoblasts (A) Antimycin (50 µg/ml) 
significantly induced ROS production in H9c2 cells from 24 minutes onwards compared to 
untreated control cells. Addition of 1 mM NaHS prevented the increase in ROS production. 
(# P<0.001 vs. control; * P<0.001 vs. NaHS) (B) Representative photomicrographs of DHE 
stained H9c2 cells treated with antimycin and NaHS showing less DHE staining (red) in the NaHS 
treated cells as compared to cells treated with only antimycin.











The major finding of this study is that administration of hypometabolic concentrations of 
gaseous H2S during myocardial IR limits the extent of myocardial damage. Furthermore, 
non-hypometabolic concentrations of H2S do not seem protective in the early phase 
after myocardial infarction, but attenuate ischemia associated processes such as fibrosis 
and ROS formation. Gaseous administration of H2S appears to be an effective way to 
attenuate the outcome of myocardial IRI, with multiple mechanisms seemingly underlying 
the protective properties.
H2S is cytoprotective during hypoxia in multiple organs. Beneficial effects of H2S 
treatment have been reported in models of shock23 and intestinal-,24 pulmonary,25 
hepatic-21,26 and renal ischemia.11 The cardio-protective effects of H2S have been 
demonstrated in models of myocardial injury. However, most of these studies use 
injection with soluble H2S donor compounds such as sodium hydrosulfide (NaHS) or 
sodium sulfide (Na2S), while no results have been published on gaseous H2S.
15-18,27 
Gaseous administration might be applicable in patients who are being ventilated because 
of cardiogenic shock, a state of brain death or during transplantation procedures. 
Inhaled H2S has beneficial effects in endotoxin induced systemic inflammation
28 and in 
experimental Parkinson’s disease.29 We previously showed protective effects of gaseous 
H2S during renal and hepatic IRI.
11,21 The benefits of gaseous administration compared 
to injections with soluble H2S donors lay within the management of the concentration. 
As opposed to injection with H2S donors it is possible to administer the gas continuously 
with a stable dose over longer periods of time. Furthermore, when treatment is stopped 
the effects vanish rapidly while leaving its positive therapeutic effects behind. Also, 
gaseous administration at higher concentrations has proven to induce a hypometabolic, 
hibernation-like state in small animals like rodents.10,11
As previously shown, 100 ppm H2S induces a hypometabolic state and lowers blood 
pressure, heart rate and CO2-production, whereas 10 ppm H2S does not.
10,11,30 A suspended 
animation-like state induced by H2S protects mice from lethal hypoxia for periods up 
to 6 hours,31 suggesting that the induction of regulated, reversible and well-controlled 
hypometabolism in organs holds clinical promise in ischemia-reperfusion related damage 
where oxygen demand exceeds oxygen availability. Although there was no difference in 
cardiac necrosis between the 10 ppm treated group and 0 ppm treated group, treatment 
with 100 ppm significantly reduced necrosis at 1 day of reperfusion. High-sensitive 
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Troponin-T (hsTnT) levels in serum were in line with this finding. This suggests that H2S 
in non-hypometabolic concentrations is not effective in preventing short-term necrosis 
caused by ischemia, and that the additional value of H2S-induced hypometabolism lies 
in the early phase of IRI. Although, the protective effects of 100 ppm H2S on necrosis 
might also be caused by a larger amount of H2S leading to increased anti-oxidant effects, 
it is difficult to distinguish between the effects of hypometabolism and other effects 
attributed to a higher dose. However, inducing a suspended animation-like state might 
be restricted to small animals like rodents. The applicability of hypometabolism in larger 
animals is still under debate and we are far from developing therapeutic applications in 
reducing metabolic rate in the clinical setting with the use of H2S.
19,20,32,33
There are a number of potential mechanisms through which H2S may exert its 
cardioprotective effects. Both 10 and 100 ppm of H2S were proven anti-inflammatory 
as evidenced by reduced granulocyte influx into necrotic areas. Treatment with H2S also 
lowered the influx of granulocytes after renal IRI.11 Furthermore, H2S inhibits neutrophil 
adhesion and activation in response to inflammatory stimuli and suppresses the release of 
the pro-inflammatory mediator tumor necrosis factor-alpha.34,35 Other studies report that 
H2S mediates pro-inflammatory effects by potentiating sulfide production in neutrophils
36 
and mediating leukocyte activation.37 Although granulocyte influx seems to be reduced by 
treatment with H2S, literature is inconclusive on the contribution of neutrophil invasion to 
final myocardial infarct size and appears not to be a dominant factor.38
We show that treatment with H2S protects against fibrosis at day 7 of reperfusion, 
as evidenced by reduced collagen deposition and fibronectin expression. Interestingly, 
the amount of necrosis differs between 10 and 100 ppm H2S at day 1 of reperfusion, 
but this does not translate into differences in fibrotic area size after 7 days. This indicates 
that treatment with both concentrations of H2S attenuate the onset of fibrosis. The 
prevention of fibrosis is in accordance with previous literature showing decreased cardiac 
remodeling and fibrosis in models of myocardial infarction and heart failure after H2S 
treatment.15,39,40 Although we find reduced fibrosis with both concentrations of H2S, a 
balanced development of fibrosis remains essential. Suppressed fibrosis with no reduction 
in the extent of necrosis predisposes to infarct expansion and tissue rupture.41 Since 10 
ppm H2S does not affect necrosis 1 day post-reperfusion, the anti-fibrotic effects at day 
7 of reperfusion are not beneficial per se.
Another functional property of H2S relates to the inhibition of ROS production, since 
the imbalance in redox status and oxidative stress contributes to fibrosis.42 ROS-generating 
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NOX2 and NOX4 are both increased after ischemic events in experimental models and 
their deficiency is protective in these models.43,44 Seven days post-reperfusion, we found 
attenuated expression of NOX2 and NOX4 in both H2S treated groups indicating less ROS 
production in vivo. We did not find an alteration of these genes at 1 day of reperfusion, 
which is in concordance with previous literature concerning NOX2.45 Although it is not 
possible to distinguish whether these components originate from the myocardium or 
from phagocytes migrated into the myocardium, these results point towards increased 
oxidative stress in the infarcted heart, and a possible beneficial involvement for the effects 
of H2S at the later time point. Furthermore, ROS production was markedly reduced in 
H2S treated cardiomyoblasts in an in vitro model of Antimycin induced oxidative stress, 
indicating direct scavenging or reduction in production of ROS by mitochondria. H2S 
has direct scavenging effects on ROS, but also has indirect effects via activation of 
antioxidant mechanisms, such as increasing glutathione levels.46,47 Another mechanism 
that could be involved is the capacity of H2S to modulate cellular respiration, as the 
inhibition of mitochondrial respiration has been shown to protect against myocardial 
IRI by limiting ROS production in mitochondria.48 Antioxidant effects of H2S may be of 
critical importance for the treatment of myocardial IRI because oxidative stress plays a 
prominent role in the development of cardiac damage and remodeling.42
The effect of exogenous H2S on blood pressure is still under debate. In vivo and 
ex vivo studies revealed conflicting responses to H2S treatment.
49-53 The effects of H2S 
on heart rate are also ambiguous; ranging from no change54 to decreased heart rate 
in others.50 Ufnal et al. noticed an increased heart rate upon NaHS infusion, however 
dependent on H2S concentration in cerebrospinal fluid.
55 In additional support of this last 
view, suppression of H2S production either pharmacologically
56 or genetically57 leads to 
an increase in blood pressure. These opposing results might be attributable to differences 
in dose and route of administration.
In this study we show that 100 ppm of gaseous H2S significantly lowers blood 
pressure and heart rate which might have affected cardiac workload and oxygen 
demand. Since we did not add a group with similar decrease in heart rate and blood 
pressure or a hypometabolic group with normal heart rate and blood pressure, we can 
not exclude this phenomenon to be responsible for the improved outcome. Aside from 
other protective effects of H2S, it is thought that the reduced demand for oxygen during 
hypometabolism might be one of the protective mechanisms during ischemia based on 
the fact that oxygen availability and oxygen expenditure are more balanced. On the other 
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hand the protective effects can not solely be explained by these effects since 10 ppm H2S 
does not alter heart rate and blood pressure and has positive effects on several damage 
parameters. Another approach might be local delivery of H2S by H2S-donors thereby 
circumventing its systemic effects, which has previously been shown to be protective.15 
However, the highly volatile nature of H2S and the associated difficulties in measuring 
this compound make it difficult to determine the exact dose and how long its effects 
endure, when given locally.
In conclusion, gaseous administration of H2S protects the heart from IRI, likely 
through reduction of myocardial ROS production and the inhibition of inflammation, 
necrosis and fibrogenesis. Hypometabolism-inducing concentrations of H2S seem to have 
additional protective effects on necrotic cell death shortly after ischemia. H2S treatment 
might be of clinical use in myocardial ischemia or cardiac transplantation, where it could 
lead to reduced myocardial damage related to hypoxia.
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